ClinicalTrials.gg
RecruitingNCT07206875DiabRegistryUpdated Nov 3, 2026

Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders

An observational study in Diabetes, Metabolic Disorders and Arterial Hypertension, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 270 studies in Diabetes Mellitus with a site in Italy — 31 open to participants now, 42 under way, 3 of them phase 3. Diabetes Mellitus · Italy.

Planned enrollment
7th of 67
10,000 · median 406
Started
2025
with 11 others
Observational
67 of 270
15 open now
Primary completion
2026-11
later than 22 of 41 live
Registered
259th of 270
by date

Among the 270 studies in Diabetes Mellitus with a site in Italy, this one is the 7th largest by planned enrollment of the 67 observational ones that give a count, is one of 12 that started in 2025, is one of 67 observational ones, reaches primary completion later than 22 of the 41 other live ones, and was the 259th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

31 of the 270 studies in Diabetes Mellitus with a site in Italy are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 270 studies in Diabetes Mellitus with a site in Italy, or all of them as a file.
02

Study summary

The main objective of this retrospective and prospective observational register is to identify anthropometric, clinical, laboratory and/or instrumental markers of disease severity and activity in patients suffering from diabetes, endocrine-metabolic disorders, rare diseases in order to improve their diagnosis, monitoring and treatment processes. The Registry is monocentric, observational prospective and retrospective. No additional procedures to those of normal clinical practice are planned, and neither diagnostic approaches nor experimental drugs/prescriptions will be applied. The data under study (demographic, anthropometric, clinical and care characteristics) will be collected as part of outpatient visits of the Diabetes Outpatient Clinic or admission to Diabetes Day Hospital.

In case of outpatients, the observation will start at the diagnosis or during the first outpatient visit and will end with the last outpatient visit performed within the total time foreseen for the duration of the study.

The study will start once the regulatory authorizations are completed, and is expected to last at least 10 years with the possibility of extension

03

Conditions studied

  • Diabetes
  • Metabolic Disorders
  • Arterial Hypertension
  • Dyslipidemia
  • Liver Disease (Alcoholic or Not)

Keywords

  • diebetes
  • metabolic disorders
  • endocrine disorders
  • observational study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diabetes and endocrine-metabolic diseases accessing the care services of the O.U. of Diabetology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Outpatient Diabetes Unit patient
  • Ability to give

Diagnosis of at least one of the following:

  • Metabolic disease, defined as ≥25 Kg/m2
  • Type 1 or type 2 diabetes mellitus
  • Gestational diabetes
  • Monogenic diabetes (MODY)
  • Other types of diabetes or dysglycemia
  • Dyslipidemia
  • Arterial hypertension
  • Steatosis liver disease (SLD)

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Deny participation at the study
  • Recruitment in an interventional protocol
  • Patients with missing significant data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Endocrine-metabolic-disase participants
06

What researchers measure

Primary outcomes

  1. GLUCOSE

    glucose in milligrams per deciliter;

    Time frame: baseline

  2. HBA1C

    glycates hemoglobin in millimoles per mole.

    Time frame: baseline

  3. Insulin

    insulin in microunits per milliliter;

    Time frame: baseline

  4. UACR

    Urine analysis: albumine in milligrams per liter, creatinine millimoles per liter.

    Time frame: baseline

  5. Anthropometric parameters

    BMI: body mass index : weight/height2 = kilogram/cm2

    Time frame: baseline

  6. c-pep

    c-peptide in nanograms per milliliter;

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • Diabetology Department, San Raffaele Scientific Institute
    Milan, Italy 20132, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 12 months is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Oct 3, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2035
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
Diabetology Department, San Raffaele Scientific Institute is now Recruiting
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    Diabetology Department, San Raffaele Scientific Institute is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07206875
Lead sponsor
IRCCS San Raffaele
Responsible party
EMANUELA SETOLA (MEDICAL DOCTOR, IRCCS San Raffaele) — Principal investigator
First posted
Oct 3, 2025
Start date
Nov 3, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2035 (estimated)
Last update
Nov 3, 2026

Study contacts

EMANUELA SETOLA, MD, PhD
Contact
setola.emanuela@hsr.it
+390226432819
AMELIA CARETTO, MD
Contact
caretto.amelia@hsr.it
+390226436283

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion